Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) Operating Expenses (2019 - 2025)

Historic Operating Expenses for aTYR PHARMA (ATYR) over the last 6 years, with Q3 2025 value amounting to $26.9 million.

  • aTYR PHARMA's Operating Expenses rose 4845.95% to $26.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.8 million, marking a year-over-year increase of 1545.37%. This contributed to the annual value of $68.1 million for FY2024, which is 2329.75% up from last year.
  • aTYR PHARMA's Operating Expenses amounted to $26.9 million in Q3 2025, which was up 4845.95% from $20.3 million recorded in Q2 2025.
  • In the past 5 years, aTYR PHARMA's Operating Expenses ranged from a high of $26.9 million in Q3 2025 and a low of $12.4 million during Q1 2022
  • Moreover, its 4-year median value for Operating Expenses was $15.9 million (2023), whereas its average is $16.5 million.
  • As far as peak fluctuations go, aTYR PHARMA's Operating Expenses plummeted by 1296.36% in 2023, and later surged by 4845.95% in 2025.
  • Over the past 4 years, aTYR PHARMA's Operating Expenses (Quarter) stood at $18.3 million in 2022, then fell by 12.96% to $16.0 million in 2023, then decreased by 0.87% to $15.8 million in 2024, then skyrocketed by 70.26% to $26.9 million in 2025.
  • Its Operating Expenses was $26.9 million in Q3 2025, compared to $20.3 million in Q2 2025 and $15.8 million in Q1 2025.